Korean J Urol.  2007 Feb;48(2):125-130. 10.4111/kju.2007.48.2.125.

Clinico-pathological Characteristics of Prostate Cancer in Korean Men and Nomograms for the Prediction of the Pathological Stage of the Clinically Localized Prostate Cancer: A Multi-institutional Update

• Song C
• Kang T
• Lee MS
• Ro JY
• Lee SE
• Lee E
• Choi HY
• Han DH
• Hong SJ
• Chung BH
• Kim CS
• Ahn H

• KMID: 2139749
• DOI: http://doi.org/10.4111/kju.2007.48.2.125

Abstract

PURPOSE: In this multi institutional study, the data of 604 men with clinically localized prostate cancer, who underwent radical prostatectomy, with updated nomograms predicting the pathological stage, were analyzed.
MATERIALS AND METHODS
Prostate biopsies and prostatectomy specimens from men treated with radical prostatectomy, obtained between 1990 and 2003, were included. The patient distribution with respect to clinical stage, serum prostate-specific antigen (PSA) and biopsy Gleason score, as well as final pathological findings, including organ-confined disease (OCD), extracapsular extension (ECE), seminal vesicle invasion (SVI), and lymph node metastasis (LNM), were analyzed for the construction of nomograms representing the percent probabilities of each respective pathological outcome.
RESULTS
The median serum PSA at the time of surgery and biopsy Gleason score were 9.9ng/ml and 7, respectively. The preoperative serum PSA was 4ng/ml or less in 38 (6.3%) patients and the tumor was impalpable in 292 (48.2%) of patients. The biopsy Gleason scores were 7 and 8 or higher in 186 (30.7%) and 169 (27.9%), respectively. Throughout the clinical stages and PSA ranges, the Gleason score was 7 or higher in more than 50% of patients, but 8-10 in 20-30%. The overall OCD, ECE, SVI and LNM rates were 57.1, 27.8, 10.9 and 4.2%, respectively. CONCLISIONS: A significantly high proportion of prostate cancers arising in Korean men exhibited poor differentiation, with Gleason scores of 7 or higher, regardless of the clinical stage or initial serum PSA. Updated nomograms acknowledging such characteristics have been developed, which may aid in the treatment planning of these individuals.

Keyword

Prostate neoplasm; Prostatectomy; Nomograms

MeSH Terms

Biopsy
Humans
Lymph Nodes
Male
Neoplasm Grading
Neoplasm Metastasis
Nomograms*
Prostate*
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms*
Seminal Vesicles
Prostate-Specific Antigen

Reference

1. Cancer Registration and Biostatistics Branch, National Cancer Center. Cancer Statistics in Korea. 2003.

2. Song C, Kim JB, Chung H, Kim CS, Ro JY, Ahn H. Nomograms for the prediction of the pathological stage of the clinically localized prostate cancer in Korean men. Korean J Urol. 2003. 44:753–758.

3. Song C, Kang T, Ro JY, Lee MS, Kim CS, Ahn H. Nomograms for the prediction of pathologic stage of clinically localized prostate cancer in Korean men. J Korean Med Sci. 2005. 20:262–266.

4. Underwood W 3rd, Jackson J, Wei JT, Dunn R, Baker E, Demonner S, et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer. 2005. 103:538–545.

5. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Longterm biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001. 28:555–565.

6. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002. 167:528–534.

7. Freedland SJ, Mangold LA, Walsh PC, Partin AW. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol. 2005. 174:1276–1281.

8. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997. 277:1445–1451.

9. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001. 58:843–848.

10. Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, et al. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0ng/ml. J Urol. 2006. 176:554–558.

11. Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C, et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol. 2004. 22:300–306.

12. Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys. 2006. 65:999–1007.

13. Steuber T, Graefen M, Haese A, Erbersdobler A, Chun FK, Schlom T, et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol. 2006. 175:939–944.

14. Ozgur A, Onol FF, Turkeri LN. Important preoperative prognostic factors for extracapsular extension, seminal vesicle invasion and lymph node involvement in cases with radical retropubic prostatectomy. Int Urol Nephrol. 2004. 36:369–373.

15. Secin FP, Bianco FJ Jr, Vickers AJ, Reuter V, Wheeler T, Fearn PA, et al. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy. Cancer. 2006. 106:2369–2375.

16. Johnson CW, Anastasiadis AG, McKiernan JM, Salomon L, Eaton S, Goluboff ET, et al. Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles. Urol Oncol. 2004. 22:107–111.

17. Ramsden AR, Chodak G. An analysis of risk factors for biochemical progression in patients with seminal vesicle invasion: validation of Kattan's nomogram in a pathological subgroup. BJU Int. 2004. 93:961–964.

18. McAleer SJ, Schultz D, Whittington R, Malkowicz SB, Renshaw A, Wein A, et al. PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urol Oncol. 2005. 23:311–317.